Evonik Industries AG/ADR
Evonik is a chemicals company based in Essen, Germany. Its products serve healthcare, automotive, electronics, cosmetics, coatings, adhesives, cleaning, pharmaceutical, paper, textile, plastics, packaging, rubber, fuel, and construction applications. The company supplies medical polymers, crosslinkers, hydrogen peroxide, silica, silanes, methionine and lysine for animal nutrition, specialty additives, and chemicals used in plastics and rubber production.
No SEC Form 4 filings for $EVKIF in the last 30 days.
See all $EVKIF insider activity →Jefferies downgraded Evonik Industries to 'hold' and cut its 2027 EBITDA forecast by 9% to below €2 billion. The brokerage raised its price target to €21 and noted that share price movements may depend on potential engagement with BASF. Evonik's EBITDA is up 14% year-to-date, but Jefferies sees challenges in reaching its 2029 ROCE target.
Evonik Industries reported a narrower net loss of €53M in Q3, down from €106M a year ago, with net sales up 13% to €3.83B. Adjusted EBITDA surged 40% to €629M. The company expects full-year adjusted EBITDA at the upper end of its €2B-€2.2B range.
Evonik Industries rejected a takeover approach from BASF, opting to remain independent. BASF had proposed a valuation of over €11 billion, up from €10.3 billion, with commitments to preserve jobs and production sites. Evonik's board reviewed the offer but decided against negotiations, reaffirming its strategic independence.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning EVKIF (Evonik Industries AG/ADR). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent EVKIF coverage spans mergers & acquisitions, financial news and earnings.
Jefferies downgraded Evonik Industries to 'hold' and cut its 2027 EBITDA forecast by 9% to below €2 billion. The brokerage raised its price target to €21 and noted that share price movements may depend on potential engagement with BASF. Evonik's EBITDA is up 14% year-to-date, but Jefferies sees challenges in reaching its 2029 ROCE target.
Evonik Industries reported a narrower net loss of €53M in Q3, down from €106M a year ago, with net sales up 13% to €3.83B. Adjusted EBITDA surged 40% to €629M. The company expects full-year adjusted EBITDA at the upper end of its €2B-€2.2B range.
Evonik Industries rejected a takeover approach from BASF, opting to remain independent. BASF had proposed a valuation of over €11 billion, up from €10.3 billion, with commitments to preserve jobs and production sites. Evonik's board reviewed the offer but decided against negotiations, reaffirming its strategic independence.
BASF CEO Markus Kamieth is pursuing a strategy called Winning Ways, focusing on core chemical business and cost reduction. The company has divested its coatings business and plans a public offering for its agricultural unit. Kamieth views acquiring Evonik Industries as a key part of this strategy.
Evonik Industries AG shares rose 5.2% after BASF SE reportedly increased its takeover offer to €11B ($12.3B), valuing Evonik at €24 per share. The offer includes job guarantees through 2032. Evonik's shares were trading at €20.86, with a market cap of €9.7B. Both companies declined to comment, and a final deal is not certain.
AlphAI scores every news story that mentions EVKIF with an AI model for sentiment and relevance, and aggregates insider trades from Evonik Industries AG/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Jefferies downgraded Evonik Industries to 'hold' and cut its 2027 EBITDA forecast by 9% to below €2 billion. The brokerage raised its price target to €21 and noted that share price movements may depend on potential engagement with BASF. Evonik's EBITDA is up 14% year-to-date, but Jefferies sees challenges in reaching its 2029 ROCE target.
Evonik Industries reported a narrower net loss of €53M in Q3, down from €106M a year ago, with net sales up 13% to €3.83B. Adjusted EBITDA surged 40% to €629M. The company expects full-year adjusted EBITDA at the upper end of its €2B-€2.2B range.
Evonik Industries rejected a takeover approach from BASF, opting to remain independent. BASF had proposed a valuation of over €11 billion, up from €10.3 billion, with commitments to preserve jobs and production sites. Evonik's board reviewed the offer but decided against negotiations, reaffirming its strategic independence.
BASF CEO Markus Kamieth is pursuing a strategy called Winning Ways, focusing on core chemical business and cost reduction. The company has divested its coatings business and plans a public offering for its agricultural unit. Kamieth views acquiring Evonik Industries as a key part of this strategy.
Evonik Industries AG shares rose 5.2% after BASF SE reportedly increased its takeover offer to €11B ($12.3B), valuing Evonik at €24 per share. The offer includes job guarantees through 2032. Evonik's shares were trading at €20.86, with a market cap of €9.7B. Both companies declined to comment, and a final deal is not certain.
BASF CEO Markus Kamieth pledged to uphold Evonik's job guarantees until 2032 amid a €10.3 billion acquisition bid. The deal, if completed, would see BASF take over its German rival.
Evonik Industries AG (EVK) rejected BASF's €10.3bn takeover bid, calling it undervalued. North Rhine-Westphalia, linked to Evonik's largest shareholder, demanded job and independence protections in any deal.
Evonik Industries' shares rose 2.6% after Reuters reported BASF may submit a new takeover offer. BASF's initial offer of €22.15 per share was rejected in September. Citi analysts estimate a potential €25 per share offer could boost BASF's earnings and cash flow by 20% through 2030, but may reduce return on invested capital to 9%.
Germany's RAG Foundation, which owns ~44% of Evonik, removed its 25.1% veto floor, allowing potential sale of its stake. BASF is exploring a takeover. Evonik's dividend policy change and RAG's financial needs are key factors. BASF aims to expand its specialty chemicals portfolio. Regulatory scrutiny expected.
Evonik Industries AG (EVKIF.PK) rejected a 10.3 billion euro acquisition offer from BASF SE (BAS.DE) as it was deemed too low. BASF offered 22.15 euros per share, valuing Evonik at 14.2 billion euros. Evonik's market cap is 8.4 billion euros, and its enterprise value is around 12 billion euros. Combined revenues of both companies were 74 billion euros last year. Evonik's shares were down 1.28 percent on the Frankfurt Exchange.
